These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8002779)

  • 1. Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1.
    Gao Q; Gu Z; Salomon H; Nagai K; Parniak MA; Wainberg MA
    Arch Virol; 1994; 136(1-2):111-22. PubMed ID: 8002779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
    Gu Z; Gao Q; Li X; Parniak MA; Wainberg MA
    J Virol; 1992 Dec; 66(12):7128-35. PubMed ID: 1279198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of nucleoside-resistant variants of HIV-1 by in vitro selection in the presence of AZT or DDI but no by combinations.
    Gao Q; Parniak MA; Gu Z; Wainberg MA
    Leukemia; 1992; 6 Suppl 3():192S-195S. PubMed ID: 1602823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.
    Shirasaka T; Yarchoan R; O'Brien MC; Husson RN; Anderson BD; Kojima E; Shimada T; Broder S; Mitsuya H
    Proc Natl Acad Sci U S A; 1993 Jan; 90(2):562-6. PubMed ID: 8380641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
    Gao Q; Gu Z; Hiscott J; Dionne G; Wainberg MA
    Antimicrob Agents Chemother; 1993 Jan; 37(1):130-3. PubMed ID: 8381634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.
    Gobert JM; Remington KM; Zhu YQ; North TW
    Antimicrob Agents Chemother; 1994 Apr; 38(4):861-4. PubMed ID: 8031060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds.
    Wondimu Z; Sönnerborg A; Ayehunie S; Britton S; Strannegård O
    Antiviral Res; 1992 Oct; 19(4):353-9. PubMed ID: 1281393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.
    Gao Q; Gu ZX; Parniak MA; Li XG; Wainberg MA
    J Virol; 1992 Jan; 66(1):12-9. PubMed ID: 1727474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains.
    Zhu QY; Scarborough A; Polsky B; Chou TC
    AIDS Res Hum Retroviruses; 1996 Apr; 12(6):507-17. PubMed ID: 8679306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates.
    Nájera I; Richman DD; Olivares I; Rojas JM; Peinado MA; Perucho M; Nájera R; López-Galíndez C
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1479-88. PubMed ID: 7534096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro.
    Mathez D; Schinazi RF; Liotta DC; Leibowitch J
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2206-11. PubMed ID: 7504908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro study of resistance-associated genotypic mutations to nucleoside analogs.
    Gashnikova N; Plyasunova O; Kiseleva Y; Fedyuk N; Pokrovsky A
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):991-4. PubMed ID: 14565328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro selection and phenotyping of HIV-1 mutants resistant to azidothymidine and didanosine].
    Kiseleva IaIu; Pliasunova OA; Pokrovskaia NV; Pokrovskiĭ AG
    Antibiot Khimioter; 2005; 50(5-6):11-6. PubMed ID: 16526603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
    Johnson VA; Merrill DP; Videler JA; Chou TC; Byington RE; Eron JJ; D'Aquila RT; Hirsch MS
    J Infect Dis; 1991 Oct; 164(4):646-55. PubMed ID: 1716649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
    Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1.
    García-Lerma JG; Gerrish PJ; Wright AC; Qari SH; Heneine W
    J Virol; 2000 Oct; 74(20):9339-46. PubMed ID: 11000201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of synergistic response to combinations containing AZT in AZT-resistant HIV-1.
    Cox SW; Albert J; Wahlberg J; Uhlén M; Wahren B
    AIDS Res Hum Retroviruses; 1992 Jul; 8(7):1229-34. PubMed ID: 1520536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.